We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

T-Cell Vaccination in Multiple Sclerosis (MS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00220428
Recruitment Status : Unknown
Verified January 2007 by Sheba Medical Center.
Recruitment status was:  Recruiting
First Posted : September 22, 2005
Last Update Posted : January 24, 2007
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to evaluate the safety of T-cell vaccination in MS patients.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Biological: T-Cell Vaccination Phase 1 Phase 2

Detailed Description:

Immunization of MS patients with irradiated autologous encephalitogenic myelin peptides (EMP) specific T-cell lines or clones.

Clinical immunologic and neuroradiologic evaluation.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Educational/Counseling/Training
Official Title: The Effect of T-Cell Vaccination in Multiple Sclerosis - Phase I/II Safety and Efficacy Trial
Study Start Date : July 1998
Estimated Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. safety assessment of T-cell vaccination in nonresponding MS patients

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   16 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Definite MS (post criteria)
  • Relapsing remitting or primary progressive clinical course. At least one relapse in the last two years.
  • Disease duration > 1 year
  • Expanded Disability Status Scale (EDSS) between 0-6
  • Brain magnetic resonance imaging (MRI) compatible with MS
  • Not involved in any other clinical trials
  • No other systemic disease

Exclusion Criteria:

  • Does not comply with the above
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00220428

Contact: Anat Achiron, MD PhD 972-3-5303932 ACHIRON@POST.TAU.AC.IL
Contact: Matilda Mandel, MD 972-3-5305309

Multiple Sclerosis Center Recruiting
Ramat Gan, Israel
Contact: Anat Achiron, MD PhD    972-3-5303932    Achiron@post.tau.ac.il   
Contact: Matilda Mandel, MD    972-3-5304081      
Principal Investigator: Anat Achiron, MD PhD         
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Anat Achiron, MD PhD Sackler School of Medicine
More Information

ClinicalTrials.gov Identifier: NCT00220428     History of Changes
Other Study ID Numbers: SHEBA-98-1754-AA-CTIL
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: January 24, 2007
Last Verified: January 2007

Keywords provided by Sheba Medical Center:
T cell

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs